DP
RLMD icon

Diadema Partners’s Relmada Therapeutics RLMD Stock Holding History

Diadema Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
200,842
-188,553
-48% -$892K 0.24% 76
2025
Q4 		$1.88M Buy
+389,395
New +$1.3M 0.32% 68

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Diadema Partners's RLMD Position: Q1 2026 in Review

Diadema Partners reduced its Relmada Therapeutics (RLMD) stake by 48% in Q1 2026, selling an estimated $892K and leaving 200,842 shares worth $1.4M. The position accounts for 0.24% of the portfolio, ranked #76.

Diadema Partners first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.88M in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Diadema Partners held 200,842 shares of Relmada Therapeutics worth $1.4M as of Q1 2026.
  • Diadema Partners sold 188,553 Relmada Therapeutics shares in Q1 2026, an estimated $892K.
  • Relmada Therapeutics made up 0.24% of Diadema Partners's portfolio in Q1 2026, its #76 holding.
  • Diadema Partners first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Diadema Partners's Relmada Therapeutics position peaked at $1.88M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.